Ernexa Therapeutics financials
$3.16−8.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $582.0K | $68.0K | $0.00 |
| Gross profit | $0.00 | $486.0K | -$168.0K | $0.00 |
| Gross margin | — | 83.5% | −247.1% | — |
| Operating income | -$9.3M | -$15.7M | -$21.1M | -$33.2M |
| Net income | -$14.1M | -$44.6M | -$21.7M | -$24.6M |
| Net margin | — | −7655.5% | −31888.2% | — |
| Diluted EPS | $-56.00 | $-1224.00 | $-1530.00 | $-3022.50 |
| EBITDA | -$9.1M | -$14.0M | -$20.6M | -$26.7M |
| Operating cash flow | -$7.0M | -$15.8M | -$20.4M | -$21.0M |
| Free cash flow | -$7.1M | -$16.2M | -$20.4M | -$21.3M |
| Diluted shares | 0.3M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $1.9M | $1.7M | $7.6M | $11.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $6.8M | $0.00 |
| Total assets | $5.8M | $5.3M | $49.1M | $22.3M |
| Total liabilities | $3.4M | $3.6M | $46.9M | $10.2M |
| Shareholders' equity | $2.4M | $1.7M | $2.2M | $12.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology